We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
178 result(s) found, displaying 11 to 20
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Prescription medicine registrationActive ingredients: fedratinib hydrochloride.
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Australian public assessment report (AusPar)Opdivo (nivolumab), in combination with platinum-doublet chemotherapy, was approved for the neoadjuvant treatment of patients with resectable non-small cell lung cancer.
-
Cancellation by sponsorRequested by Bristol-Myers Squibb Australia Pty Ltd
-
Cancellation by sponsorRequested by Bristol-Myers Squibb Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Australian public assessment report (AusPar)Opdualag (Nivolumab and Relatlimab) has been approved for the treatment of patients with unresectable or metastatic melanoma who are at least 12 years old.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOTYKTU deucravacitinib 6 mg film-coated tablet blister pack.